首页 > 市场调查报告书 > 製药

神经疾病

多发性硬化症药物市场规模、份额和成长分析（按药物类别、通路、给药途径和地区划分）—产业预测（2026-2033 年）

市场调查报告书

商品编码

1898601

多发性硬化症药物市场规模、份额和成长分析（按药物类别、通路、给药途径和地区划分）—产业预测（2026-2033 年）

Multiple Sclerosis Drugs Market Size, Share, and Growth Analysis, By Drug Class (Immunosuppressant and Immunomodulators), By Distribution Channel (Hospital, Pharmacy), By Mode of Administration, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，多发性硬化症治疗市场规模将达到 296.2 亿美元，到 2025 年将成长至 308.9 亿美元，到 2033 年将成长至 432.7 亿美元，预测期（2026-2033 年）的复合年增长率为 4.3%。

由于多发性硬化症 (MS) 的盛行率和疾病负担日益加重，且该疾病会影响多种生理功能，因此多发性硬化症治疗市场正经历显着增长。对有效治疗方法的需求不断增长，推动了创新化疗药物的需求。各大製药公司正大力投资研发新型治疗方法，药物製剂方面也取得了最新进展，例如用于家庭治疗的鼻内抗 CD3 单株抗体。此外，旨在改善治疗可近性的新产品上市和政府措施也进一步推动了市场扩张。这些因素，加上对新疗法的持续追求，使得多发性硬化症治疗市场前景广阔，为产业相关人员提供了盈利的机会。

多发性硬化症药物市场驱动因素

全球多发性硬化症 (MS) 的盛行率不断上升，导致对 MS 药物的需求显着增长。数以百万计的人饱受这种疾病的折磨，尤其是在已开发地区，因此迫切需要能够有效延缓和控制疾病进展的创新治疗方法。随着人们对 MS 的认识不断提高以及诊断能力的进步，越来越多的患者被发现，从而扩大了需要新治疗方案的患者群体。这种对有效治疗方案日益增长的需求正在重塑 MS 药物的市场格局，并凸显了推动医疗技术发展的迫切性。

限制多发性硬化症药物市场的因素

多发性硬化症 (MS) 的高昂治疗费用是市场扩张的一大障碍。包括化疗和各种口服药物在内的疾病修正治疗价格通常价格分布，使得没有全面医疗保险的患者难以负担。这项经济挑战在中低收入国家尤其严峻，这些国家的医疗体系往往缺乏足够的资源来提供这些先进的疗法。因此，许多 MS 患者无法获得所需的治疗，这不仅限制了整体市场潜力，也限制了更多患者群体可获得的治疗方案。

多发性硬化症治疗药物市场趋势

在多发性硬化症药物市场，个人化医疗和基于生物标记的治疗方法正迅速发展。遗传学和分子生物学的进步推动了特定生物标记的识别，从而改变了治疗策略，使医疗服务提供者能够预测疾病进展并根据患者的个别特征量身定制治疗方案。这种转变不仅提高了治疗效果，而且透过针对每位患者独特的生物学特征调整治疗方案，最大限度地减少了副作用。随着对个人化医疗的日益重视，製药公司正大力投资研发，为满足多发性硬化症患者的多样化需求而开发创新解决方案。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Biogen Inc.（United States）
Roche Holdings AG（Switzerland）
Novartis AG（Switzerland）
Sanofi SA（France）
Merck & Co., Inc.（United States）
Teva Pharmaceutical Industries Ltd.（Israel）
Bayer AG（Germany）
Pfizer Inc.（United States）
GlaxoSmithKline plc（United Kingdom）
AbbVie Inc.（United States）
Johnson & Johnson Services, Inc.（United States）
Celgene Corporation（United States）
Bristol-Myers Squibb Company（United States）
Mitsubishi Tanabe Pharma Corporation（Japan）
Biogen Idec International GmbH（Switzerland）
Genzyme Corporation（United States）
F. Hoffmann-La Roche Ltd（Switzerland）
Merck KGaA（Germany）
Mylan NV（United States）

结论与建议

简介目录

Product Code: SQMIG35I2199

Multiple Sclerosis Drugs Market size was valued at USD 29.62 Billion in 2024 and is poised to grow from USD 30.89 Billion in 2025 to USD 43.27 Billion by 2033, growing at a CAGR of 4.3% during the forecast period (2026-2033).

The market for multiple sclerosis (MS) drugs is experiencing significant growth due to the rising prevalence and burden of the disease, which impacts various bodily functions. This growing need for effective therapies is prompting increased demand for innovative chemotherapeutics. Major pharmaceutical companies are heavily investing in research and development to create novel treatments, with recent advancements in drug formulations, including intranasal anti-CD3 monoclonal antibodies designed for at-home use. Additionally, product launches and government initiatives aimed at improving treatment accessibility are further propelling market expansion. These factors, coupled with the ongoing push for new therapeutic options, indicate a promising outlook for the multiple sclerosis drug market, presenting lucrative opportunities for industry stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Multiple Sclerosis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Multiple Sclerosis Drugs Market Segments Analysis

Global Multiple Sclerosis Drugs Market is segmented by Type, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Immunomodulators, Interferons, Immunosuppressants and Other types. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Other Distribution Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Multiple Sclerosis Drugs Market

The rising incidence of multiple sclerosis (MS) globally significantly propels the demand for multiple sclerosis drugs. With millions of individuals affected by this condition, particularly in more developed regions, there is a pressing need for innovative treatments to effectively address and manage the progression of the disease. As awareness of MS expands and diagnostic capabilities improve, more patients are being identified, thereby increasing the overall patient population that necessitates new therapeutic options. This growing demand for effective treatment solutions is shaping the landscape of the multiple sclerosis drugs market, highlighting the urgency for advancements in medical therapies.

Restraints in the Multiple Sclerosis Drugs Market

The high cost associated with Multiple Sclerosis (MS) treatments presents a significant obstacle to market expansion. Disease-modifying therapies, including chemotherapy and various oral medications, are frequently priced at premium levels, rendering them inaccessible for patients lacking comprehensive insurance. This financial challenge is particularly severe in low- and middle-income nations, where healthcare systems often lack the necessary resources to provide such advanced treatments. As a result, many individuals suffering from MS are unable to receive the care they need, hindering overall market potential and limiting the advancement of therapeutic options available to a broader patient population.

Market Trends of the Multiple Sclerosis Drugs Market

The Multiple Sclerosis drugs market is increasingly embracing the trend of personalized medicine and biomarker-based therapies. Fueled by advancements in genetics and molecular biology, the ability to identify specific biomarkers is transforming treatment strategies, enabling healthcare providers to predict disease progression and tailor therapies to individual patient profiles. This shift not only enhances treatment efficacy but also minimizes adverse effects by aligning therapeutic approaches with the unique biological characteristics of each patient. As the focus on customized care grows, pharmaceutical companies are investing heavily in research and development, paving the way for innovative solutions that cater to the diverse needs of those living with Multiple Sclerosis.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Multiple Sclerosis Drugs Market Size by Type & CAGR (2026-2033)

Market Overview
Immunomodulators
Interferons
Immunosuppressants
Other types

Global Multiple Sclerosis Drugs Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Parenteral
Others

Global Multiple Sclerosis Drugs Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Other Distribution Channels

Global Multiple Sclerosis Drugs Market Size & CAGR (2026-2033)

North America (Type, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Biogen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holdings AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mitsubishi Tanabe Pharma Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Idec International GmbH (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genzyme Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments